Biosergen, Alkem collaborate to develop anti-infective for severe fungal infections
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
With All India Institute of Ayurveda as a knowledge partner and Sodexo’s culinary expertise, Aarogyum is a well-rounded offering in patient dining solutions
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Nous-209 has been developed using the Nouscom's viral vector platform
Study efficacy measures will include the expression of dystrophin protein and motor function.
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Subscribe To Our Newsletter & Stay Updated